TY - JOUR
T1 - In vitro anti-diabetic potential of medicinal herbs commonly used in the Ayurvedic system of Sri Lanka with comprehensive metabolite profiling of Phyllanthus emblica using GC-MS and LC-HRMS
AU - Ariyarathna, Pathumi
AU - Wickramarachchi, Dhanushki
AU - Visvanathan, Rizliya
AU - Qader, Mallique
AU - Deen, Afka
AU - Rathnayaka, Isuri
AU - Rateb, Mostafa E.
AU - Liyanage, Ruvini
PY - 2025/1/22
Y1 - 2025/1/22
N2 - This study assessed the in vitro anti-diabetic potential and bioactive constituents of ten Sri Lankan medicinal herbs. Initial screening of aqueous extracts for starch-digesting enzyme inhibition prioritised three plants with notable activity (p ≤ 0.05), for further assessment using methanolic extracts: Phyllanthus emblica (PE), Cassia auriculata (CA), and Hemidesmus indicus (HI). The selected plants were tested for starch-digesting enzyme inhibition, cytotoxicity, and bioactive metabolite identification, with PE subjected to GC-MS and LC-HRMS analyses. All three extracts contained alkaloids, flavonoids, tannins, and terpenoids, except saponins and steroids in PE. GC-MS analysis of PE annotated ten compounds, eight with anti-diabetic properties, while LC-HRMS annotated thirty metabolites, including fourteen anti-diabetic compounds. Cell viability assessments confirmed the non-toxic nature of PE, CA, and HI. The significant enzyme inhibition and non-toxic nature of PE highlight its potential to treat type 2 diabetes. Further in vivo and clinical studies are essential to determining effective dosage and toxicity levels.
AB - This study assessed the in vitro anti-diabetic potential and bioactive constituents of ten Sri Lankan medicinal herbs. Initial screening of aqueous extracts for starch-digesting enzyme inhibition prioritised three plants with notable activity (p ≤ 0.05), for further assessment using methanolic extracts: Phyllanthus emblica (PE), Cassia auriculata (CA), and Hemidesmus indicus (HI). The selected plants were tested for starch-digesting enzyme inhibition, cytotoxicity, and bioactive metabolite identification, with PE subjected to GC-MS and LC-HRMS analyses. All three extracts contained alkaloids, flavonoids, tannins, and terpenoids, except saponins and steroids in PE. GC-MS analysis of PE annotated ten compounds, eight with anti-diabetic properties, while LC-HRMS annotated thirty metabolites, including fourteen anti-diabetic compounds. Cell viability assessments confirmed the non-toxic nature of PE, CA, and HI. The significant enzyme inhibition and non-toxic nature of PE highlight its potential to treat type 2 diabetes. Further in vivo and clinical studies are essential to determining effective dosage and toxicity levels.
KW - medicinal plants
KW - anti-diabetic
KW - starch-digesting enzyme
KW - GC-MS
KW - LC-HRMS
U2 - 10.1080/14786419.2025.2454367
DO - 10.1080/14786419.2025.2454367
M3 - Article
SN - 1478-6419
JO - Natural Product Research
JF - Natural Product Research
M1 - 2454367
ER -